Dendritic Cells in Tumor Immunology

  • Morikazu Onji


The mechanisms underlying tumorigenesis of various organs and tissues might share some common features, but it is likely that some organ-specific factors influence tumorigenesis in a particular organ. For example, the cellular and molecular events underlying the development of solid tumors would be different from those underlying tumors of blood cells. Some tumors develop from a malignant state, whereas in other cases, apparent premalignant conditions, even if present, are not well characterized. For example, tumors of liver cells, hepatocellular carcinoma (HCC), usually develop from a definitive precancerous state. Similarly, microbial infections or chemical carcinogens might induce chronic inflammatory changes in several organs that could make them susceptible to malignant transformation. In addition, various other factors, most of which are still elusive, might induce tumorigenesis.


Antitumor Immunity Tumor Immunology Cancer Microenvironment Cancer Nodule Allostimulatory Capacity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Recommended Readings

  1. Byrne SC, Hallyday GM (2002) Dendritic cells: making progress with tumor regression. Immunol Cell Biol 80:520–530PubMedCrossRefGoogle Scholar
  2. Brossart P, Wirths S, Brugger W, et al. (2001) Dendritic cells in cancer vaccines. Exp Hematol 29:1247–1255PubMedCrossRefGoogle Scholar
  3. Dallal RM, Lotze MT (2000) The dendritic cell and human cancer vaccines. Curr Opin Immunol 12:583–588PubMedCrossRefGoogle Scholar
  4. Fong L, Engleman EG (2002) Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18:245–273CrossRefGoogle Scholar
  5. Gunzer M, Janich S, Varga G, et al. (2001) Dendritic cells and tumor immunity. Semin Immunol 13:291–302PubMedCrossRefGoogle Scholar
  6. Hart DN (1997) Dendritic Cells: unique leukocyte populations which control the primary immune respone. Blood 90:3245–3287PubMedGoogle Scholar
  7. Matsue H, Kusuhara M, Matsue K, et al. (2002) Dendritic cell-based immunoregulatory strategies. Int Arch Allergy Immunol 127:251–258PubMedCrossRefGoogle Scholar
  8. Nestle FO (2002) Dendritic cell vaccination for cancer therapy. Oncogene 19:6673–6679CrossRefGoogle Scholar
  9. Onji M, Akbar SMF, Horiike N (2001) Dendritic cell-based immunotherapy for hepatocellular carcinoma. J Gastroenterol 36:794–797PubMedCrossRefGoogle Scholar
  10. Schuler G, Schuler-Thurner B, Steinman RM (2003) The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15:138–147PubMedCrossRefGoogle Scholar
  11. Sprinzi GM, Kacani L, Schrott-Fischer A, et al. (2001) Dendritic cell vaccines for cancer therapy. Cancer Treat Rev 27:247–255CrossRefGoogle Scholar
  12. Steinman RM, Dhodapkar M (2001) Active immunization against cancer with dendritic cells: the near future. Int J Cancer 94:459–473PubMedCrossRefGoogle Scholar
  13. Steinman RM, Pope M (2002) Exploiting dendritic cells to improve vaccine therapy. J Clin Invest 109:1519–1526PubMedGoogle Scholar
  14. Tatsumi T, Storkins WJ (2002) Dendritic cell-based vaccines and therapies for cancers. Expert Opin Biol Ther 2:919–928PubMedCrossRefGoogle Scholar

Copyright information

© Morikazu Onji 2004

Authors and Affiliations

  • Morikazu Onji
    • 1
  1. 1.Third Department of Internal MedicineEhime University School of MedicineOnsen-gun, EhimeJapan

Personalised recommendations